KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Change in Accured Expenses (2020 - 2025)

Boston Scientific's Change in Accured Expenses history spans 6 years, with the latest figure at $285.0 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 25.97% year-over-year to $285.0 million; the TTM value through Dec 2025 reached $296.0 million, up 21.81%, while the annual FY2025 figure was $296.0 million, 21.81% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $285.0 million at Boston Scientific, up from $165.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $385.0 million in Q4 2024 and bottomed at -$450.0 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $47.0 million (2023), against an average of $40.5 million.
  • The largest annual shift saw Change in Accured Expenses plummeted 5357.14% in 2022 before it skyrocketed 1573.91% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $133.0 million in 2021, then surged by 151.88% to $335.0 million in 2022, then plummeted by 93.13% to $23.0 million in 2023, then surged by 1573.91% to $385.0 million in 2024, then decreased by 25.97% to $285.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Change in Accured Expenses are $285.0 million (Q4 2025), $165.0 million (Q3 2025), and $231.0 million (Q2 2025).